 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ABV-1501 / ABVC BioPharma
Trial completion date, Trial primary completion date, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.
Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
- | ABV-1501 / ABVC BioPharma
Trial completion date, Trial primary completion date, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.
Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Oct 2024 --> Apr 2025 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Oct 2023 --> Oct 2024
- | ABV-1501 / ABVC BioPharma
Trial completion date, Trial primary completion date, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Jul 20, 2022
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.
Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Oct 2022 --> Oct 2023
- | ABV-1501 / ABVC BioPharma
Trial completion date, Trial primary completion date, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Jan 15, 2020
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.
Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Oct 2022 --> Oct 2023 Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Oct 2021 --> Oct 2022
- | ABV-1501 / ABVC BioPharma
Trial completion date, Trial primary completion date, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Apr 12, 2019
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.
Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial completion date: Sep 2018 --> Feb 2022 | Trial primary completion date: Jun 2018 --> Oct 2021
- | ABV-1501 / ABVC BioPharma
New P1/2 trial, Monotherapy, Surgery, Metastases: Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=44, Not yet recruiting, Sponsor: BioLite, Inc.